EBS News and Press, Emergent Biosolutions Inc. From 05/12/21

Emergent BioSolutions (EBS) executives are set to testify before the House Select Subcommittee on the Coronavirus on May 11.The beleaguered company is trying to recover from a series of setbacks related to its contract manufacture of COVID-19 vaccine for Johnson & Johnson (JNJ).The meetin...

Emergent Biosolutions (EBS), whose Baltimore plant has drawn the scrutiny of the FDA, says it has initiated a comprehensive quality enhancement plan for the facility.The plant is where a manufacturing mix-up in late March ruined 15M Johnson & Johnson (JNJ) COVID-19 vaccine doses.The compa...

Radnor, Pennsylvania--(Newsfile Corp. - May 11, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired ...

Distribution of millions of doses of Johnson & Johnson's (JNJ) COVID-19 vaccine are on hold in Canada, Europe and South Africa because they were made at an Emergent BioSolutions (EBS) plant with manufacturing issues, according to The New York Times.Authorities in those countries want to m...

GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VI...

Shares of Emergent BioSolutions (NYSE: EBS) fell 30% in April, according to data from S&P Global Market Intelligence , after quality-control errors at one of the company's facilities ruined millions of doses of Johnson & Johnson 's COVID-19 vaccine. The purge...

Shares of Emergent Biosolutions Inc. (NYSE:EBS) traded at a new 52-week low today of $59.54. This new low was reached on below average trading volume as 196,000 shares traded hands, while the average 30-day volume is approximately 1 million shares. In the past 52 weeks, Emergent Biosolut...

Bad news can be good news if you're an investor with a long time horizon and guts of steel. Every time a stock takes a body blow from an ugly reveal, there's an opportunity to buy at a discount. That's the logic that might lead someone to consider picking up a few shares of Emergent B...

Emergent BioSolutions has had a rough go over the past couple of months resulting from a cross-contamination mishap at their Baltimore facility. Due to the cross contamination, the company had to toss millions of Johnson & Johnson vaccines. Consequently, the FDA put a halt on vacc...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Emergent BioSolutions Inc. 2021 Q1 - Results - Earnings Call Presentation